It is worthwhile to give patients expensive new drugs that can cure their hepatitis C much earlier than some insurers are now willing to pay for them, according to a UC San Francisco study that models ...

(Reuters) - Gilead Sciences Inc said its experimental hepatitis C drug sofosbuvir, in a late-stage clinical study, was clearly superior to historical cure rates at both 12 and 16 weeks of treatment in ...

Ashwin Dhanda does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...

New medications called direct-acting antivirals (DAAs) have transformed the treatment of hepatitis C. Twelve weeks on one of these drugs cures the infection in 95 percent or more of people who take it ...

ZURICH, Nov 2 (Reuters) - Swiss drugmaker Roche Holding AG says it has moved its investigational hepatitis C drug R1626 into a new mid-stage trial after it showed promising results in combination with ...

Atea is preparing for the Phase 3 program, which is expected to follow an End of Phase 2 meeting with the FDA anticipated for early 2025. The Phase 3 program is expected to use a fixed-dose ...